For example, adjuvant therapy with pan-HER2 tyrosine-kinase inhibitor neratinib significantly improved invasive disease-free survival in women after chemotherapy and trastuzumab-based adjuvant therapy with HER2-positive early-stage breast cancer [33]. This evidence concerns the gene ERBB2 and breast cancer.